T. Rowe Price Associates
TSHA icon

T. Rowe Price Associates’s Taysha Gene Therapies TSHA Stock Holding History

T. Rowe Price Associates’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$711K Buy
158,954
+37,140
+30% +$173K ﹤0.01% 2300
2025
Q4 		$670K Buy
121,814
+7,979
+7% +$38.7K ﹤0.01% 2267
2025
Q3 		$373K Buy
113,835
+29,232
+35% +$82.8K ﹤0.01% 2500
2025
Q2 		$196K Buy
84,603
+10,578
+14% +$23K ﹤0.01% 2722
2025
Q1 		$103K Buy
74,025
+8,694
+13% +$14.5K ﹤0.01% 2816
2024
Q4 		$114K Buy
65,331
+5,612
+9% +$11.6K ﹤0.01% 2812
2024
Q3 		$121K Sell
59,719
-1,216,859
-95% -$2.67M ﹤0.01% 2784
2024
Q2 		$2.86M Buy
1,276,578
+177,249
+16% +$516K ﹤0.01% 1411
2024
Q1 		$3.16M Sell
1,099,329
-128,004
-10% -$267K ﹤0.01% 1367
2023
Q4 		$2.17M Sell
1,227,333
-20,138
-2% -$40.1K ﹤0.01% 1483
2023
Q3 		$3.94M Buy
+1,247,471
New +$2.33M ﹤0.01% 1231

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates's TSHA Position: Q1 2026 in Review

T. Rowe Price Associates increased its Taysha Gene Therapies (TSHA) stake by 30% in Q1 2026, buying an estimated $173K and bringing the position to 158,954 shares worth $711K. The position accounts for ﹤0.01% of the portfolio, ranked #2300.

T. Rowe Price Associates first reported a position in TSHA in Q3 2023 and has held it in 11 quarters since. The position peaked at $3.94M in Q3 2023. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • T. Rowe Price Associates held 158,954 shares of Taysha Gene Therapies worth $711K as of Q1 2026.
  • T. Rowe Price Associates bought 37,140 Taysha Gene Therapies shares in Q1 2026, an estimated $173K.
  • Taysha Gene Therapies made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2300 holding.
  • T. Rowe Price Associates first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 11 quarters since.
  • T. Rowe Price Associates's Taysha Gene Therapies position peaked at $3.94M in Q3 2023.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.